SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Anticipation of Microns upcoming earnings is driving attention, with traders focusing on AI-related demand, tight DRAM/HBM supply, rising memory prices and expectations for strong results. Bullish participants see sustained pricing power and data-center growth, while skeptics cite cyclicality, elevated valuations, rates and potential AI-spending weakness as risks.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

A broad semiconductor and AI-stock rebound, fueled by renewed confidence in data-center demand and tight chip supply, has driven heavy bullish attention around AMD; reports that AMD may raise chip prices as TSMC wafer costs rise are adding to the discussion. Traders are positioning for continued momentum, while others warn that elevated valuation, overbought conditions and options expiration could bring a pullback.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

A sharp NEAR rally has drawn attention amid broader altcoin momentum, with traders citing short liquidations and renewed interest in NEARs AI-agent, chain-abstraction and NEAR Intents utility. Some community members view fee-driven buybacks and adoption as support for the move, while others call it a news-free, whale-driven pump vulnerable to reversal.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyxs full FDA approval of Fayuvi, the first treatment for Sanfilippo syndrome type A, is driving attention, with traders focused on the commercial launch, Priority Review Voucher, and potential revenue impact. The community is broadly bullish, though some argue the initial gain was muted and caution that the ultra-rare patient population, treatment-label restrictions, cash burn, and profit-taking could limit near-term upside.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Attention centers on SpaceXs Starship Flight 14, now targeted for September 28 after delays, with traders viewing a successful orbital test as a potential catalyst while others question launch readiness and cite lockup-related supply and valuation risks. Nasdaq-100 rebalancing, options positioning, and quadruple-witching expiration are also adding to the debate over heightened volatility.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Uncertainty around Reddits Google AI/data-licensing renewal is the dominant focus, intensified by CEO commentary that negotiations remain active without a concrete deal. Traders are split between viewing potential renewal terms and improving user growth as upside catalysts, while bears point to the lack of an agreement, management concerns, and continued insider selling as reasons for weakness.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

A sharp SHIB rebound and renewed meme-coin momentum are driving attention, with traders highlighting rising volume, higher highs and increased trending visibility. The community is largely bullish and adding or holding positions, although some traders view the move as a recurring pump-and-dump pattern and remain skeptical of SHIBs long-term prospects.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

A definitive U.S. Department of Commerce CHIPS Act agreement to fund Rigettis superconducting quantum-computing R&D and take a minority equity stake has driven attention alongside a broader quantum-sector rally. Traders view the government backing as validation and potential momentum catalyst, while others focus on dilution, the fact that the news is largely priced in, and Rigettis limited commercial progress.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

A second fiscal 2026 guidance cut, driven by continued ramp-up and supply-chain problems at Fluences Houston contract-manufacturing facility, has intensified concerns about execution and delayed backlog conversion. Traders are split between viewing the selloff and analyst downgrades as an overshoot with strong demand and short-squeeze potential, and arguing that repeated cuts have damaged management credibility.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is drawing attention after reports that SK Hynix is exploring a partnership to manufacture memory chips at Intels planned Ohio facility, potentially supporting Intels foundry strategy amid strong AI-related memory demand. Traders are broadly bullish on the prospect, though others caution that discussions remain exploratory and no agreement has been finalized.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally?

Equity

Palisade Bio received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for PALI-2108, an ulcerative colitis treatment.

Verra Mobility, Zscaler, Box And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Stock futures rise on Wednesday, with Verra Mobility's shares plunging 45% after Avis Budget Group terminated its agreement with the company. Other stocks moving lower in pre-market trading include Zscaler, Brain, LG Display, Zepp Health, Globalfoundries, Posco Holdings, Insulet, Palisade Bio...

Palisade Bio, Inc. (NASDAQ:PALI) Receives Average Recommendation of "Moderate Buy" from Brokerages

Palisade Bio, Inc. (NASDAQ:PALI - Get Free Report) has received an average recommendation of 'Moderate Buy' from the eight analysts that are presently covering the firm, MarketBeat reports. One...

Palisade Bio (PALI) Expected to Announce Earnings on Monday

Palisade Bio (NASDAQ:PALI) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-palisade-bio-inc-stock...

These Stocks Could Rip into the Close

As the market barrels into the final hour of trading, momentum is clustering around a powerful trio of themes, AI infrastructure, next-gen materials, and sustainable agriculture. $KBLB, $LOCL, $MRVL, $POET, $PALI, $FFAI

Analysts Offer Predictions for Palisade Bio Q1 Earnings

Palisade Bio, Inc. (NASDAQ:PALI - Free Report) - Investment analysts at Brookline Capital Markets issued their Q1 2026 earnings per share (EPS) estimates for Palisade Bio in a research note issued to...

Brokers Issue Forecasts for Palisade Bio Q3 Earnings

Palisade Bio, Inc. (NASDAQ:PALI - Free Report) - Stock analysts at Brookline Capital Markets issued their Q3 2026 EPS estimates for Palisade Bio in a research report issued on Wednesday, April 15th. Brookline Capital Markets analyst K. Raja expects that the company will earn ($0.06) per share for th...

Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Palisade Bio, Inc. (NASDAQ:PALI - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight brokerages that are covering the company, MarketBeat Ratings reports...

Wolfe Research Upgrades Palisade Bio (NASDAQ:PALI) to Strong-Buy

Wolfe Research upgraded shares of Palisade Bio to a "strong-buy" rating in a report on Wednesday...

Wolfe Research Begins Coverage on Palisade Bio (NASDAQ:PALI)

Wolfe Research assumed coverage on shares of Palisade Bio in a report on Thursday. They set an "outperform" rating and a $7.00 price objective for the company...

This account has been verified as an official PALI representative.

Verified Account

Palisade Bio

Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company advancing a next-generation oral PDE4 inhibitor prodrug designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases.

The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. PALI-2108 has demonstrated positive results in a Phase 1a and two Phase 1b clinical trials, including studies in ulcerative colitis (UC) and fibrostenotic Crohn’s Disease (FSCD).

Palisade Bio is now advancing towards two Phase 2 clinical studies in UC and Crohn’s disease (CD).

Palisade Bio Inc

Bullish Sentiment

No more this year

One more

Two more

The Federal Reserve raised interest rates by a quarter point to a range of 3.75%-4.00% on Wednesday, its first hike since July 2023, but Fed Chair Kevin Warsh signaled the tightening cycle isn't over. How many more rate hikes do you expect by the end of 2026? Vote and explain your reasoning in the comments.

The Fed hiked rates 25bps yesterday, its first since 2023, but signaled it&#39;s not done - projections point to one or two more hikes this year. How many total hikes do you expect by year-end?

Stocktwits

The Fed hiked rates 25bps yesterday, its first since 2023, but signaled it's not done - projections point to one or two more hikes this year. How many total hikes do you expect by year-end?

Current Price	$1.70
Prev Close	$1.69
Open	$1.75
Dividend Yield	0.00%
50-Day Moving Average	$2.01
Beta	0.85
Avg. Volume	1.58M
PE Ratio	-3.18

52-Week High	$2.86
52-Week Low	$0.58
Market Capitalization	$294.52M
EPS (Annual)	-$0.3014
Price to Book	2.42
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

PALI Fundamentals